OR WAIT null SECS
More than 50% of patients with schizophrenia are estimated to be nonadherent with their antipsychotic medication regimen. What treatment solutions are available?
One of the biggest challenges in treating schizophrenia is patient nonadherence to prescribed medications. Estimates suggest more than 50% of patients are partially or fully nonadherent with their antipsychotic medication regimens.
Long acting injections (LAI) may be the solution to this problem. Janssen Pharmaceutical Companies of Johnson & Johnson recently announced their supplemental New Drug Application (sNDA) submission for paliperidone palmitate 6-month (PP6M), a treatment for adults diagnosed with schizophrenia. PP6M will be the first and only long-acting injectable (LAI) medication for schizophrenia with a bi-annual dosing regimen, if approved.
To read more about this, see Six-Month Long-Acting Treatment for Schizophrenia in the Works.
Dr Gopal is the Head of Development Psychiatry at Janssen R&D (Johnson & Johnson). Follow him on Twitter: @sgopal2